应用Oncotype DX检测评估标准参数下生物学行为不确定的早期ER阳性HER2阴性乳腺癌患者复发风险及其对治疗推荐影响的前瞻性研究:POST试验
POST试验是在意大利托斯卡纳地区14个乳腺中心开展的多中心前瞻性队列研究,纳入标准参数下生物学行为不确定的pT1-2 pN0-N1mi激素受体阳性/HER2阴性早期乳腺癌患者,按复发评分(RS)分为低危(<11)、中危(11-25)和高危(>25)组,评估RS对治疗推荐的影响。246例检测样本中65.4%为中危,RS结果出来后15.9%的病例治疗推荐发生改变;初始推荐化疗或讨论化疗作用的患者中分别有64.3%和75.9%最终仅推荐内分泌治疗。研究提示RS结果可优化初始推荐或考虑化疗的生物学行为不确定早期乳腺癌患者的治疗决策。
要点
- 246例检测样本中65.4%为RS中危(11-25),仅78例归为低危或高危。
- RS结果出来后15.9%的病例治疗推荐发生改变。
- 初始推荐化疗或讨论化疗作用的患者中,分别64.3%和75.9%最终仅推荐内分泌治疗。
核心结论
- 研究提示RS结果可优化初始推荐或考虑化疗的生物学行为不确定早期乳腺癌患者的治疗决策。
研究设计与样本
- POST试验为多中心前瞻性队列研究,在意大利托斯卡纳地区14个乳腺中心开展。
- 连续纳入标准参数下生物学行为不确定的pT1-2 pN0-N1mi激素受体阳性/HER2阴性早期乳腺癌患者。
主要发现
- 246例检测样本中78例归为低危或高危,大多数患者(65.4%)为RS中危。
- RS结果出来后15.9%的病例治疗推荐发生改变。
- 初始推荐化疗的患者中64.3%最终仅推荐内分泌治疗。
- 初始推荐讨论化疗作用的患者中75.9%最终仅推荐内分泌治疗。
关键数值与推荐
- RS<11为低危组,RS 11-25为中危组,RS>25为高危组。
- 治疗推荐由多学科会议在RS结果获取前后分别评估。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Data published in 2015 showed that patients with early breast cancer (EBC) and a low-risk (LR) Recurrence Score® (RS) result by the 21-gene Oncotype DX® assay ("the test") did not derive benefit from adding chemotherapy (CT) to endocrine therapy (HT), while those with a high-risk (HR) RS result did. However, the role of CT remained uncertain in patients with intermediate-risk (IR) cancers. We designed a study to assess the test's ability to categorize patients with EBC with uncertain biological behavior into the groups (LR and HR) for which the value of additional chemotherapy was defined. METHODS: The POST trial was a multicenter, prospective cohort study conducted in 14 Breast Centers of the Tuscany region of Italy. Consecutive patients with pT1-2 pN0-N1mi hormone receptor-positive/HER2-negative EBC and uncertain biological behavior based on standard parameters were enrolled. Patients were categorized based on RS results into LR, IR, and HR groups if RS result was < 11, 11-25, and > 25, respectively. Treatment recommendations by multidisciplinary meeting assessed before and after RS results were available. RESULTS: Of 246 tested samples, 78 were classified as LR or HR, with most of the patients (65.4 %) being at IR. Following test results, the recommendation changed in 15.9 % of cases. Among patients initially recommended for CT or for discussion about the role of CT, respectively 64.3 % and 75.9 % ultimately received recommendation for HT alone. CONCLUSIONS: Our study suggests that RS results can refine treatment decisions for patients with EBC exhibiting uncertain biological behavior initially recommended or considered for CT. (250/250).
引用
- Livraghi L, Martella F, Ghilli M, et al. Prospective study on Oncotype DX® assay to assess recurrence risk in early ER-positive HER2-negative breast cancer patients with uncertain biological behavior by standard parameters and its impact on treatment recommendation: The POST trial. Eur J Cancer. 2024. PMID: 39522332. doi:10.1016/j.ejca.2024.115108
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。